Labcorp (LH)
Health Care · diagnostic laboratories and research services · NYSE
Labcorp is a leading global life sciences company providing essential clinical diagnostic testing and drug development services to the healthcare industry.
What Labcorp does
Labcorp is a global life sciences company that provides vital diagnostics and drug development services. The company operates through two primary segments: Diagnostics Laboratories (Dx), which provides comprehensive clinical laboratory testing, and Biopharma Laboratory Services (BLS), which offers specialized research and development support for pharmaceutical and biotechnology companies.
Themes: diagnostics testing, drug development outsourcing, precision medicine, biopharma services, clinical trials
Fundamentals
- Price$314.20 as of 2026-10-08 close
- Market cap$25.5B as of 2026-08-04 (share count; price 2026-10-08)
- 1-year return+13.2% 2025-10-08 close $277.51 → 2026-10-08 close $314.20
- P/E25.98 as of 2026-10-08
- Net margin+6.3% FY2025, SEC XBRL
- Gross margin+28.8% FY2025, SEC XBRL
- ROE+10.2% FY2025, SEC XBRL
- Debt / equity0.69 as of 2026-09-03
- Revenue growth (YoY)+6.4% as of 2026-09-03
- Revenue CAGR (3y)+5.6% SEC XBRL
- Beta0.54 as of 2026-09-03
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.9%; at least 4 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How LH compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginbottom 25% 189 covered Health Care peers, as of 2026-09-03
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldmiddle range 72 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
LH is not currently in any published Top 10 list. Its scores are below.
Top 10 score
50.7 #687 of 1,379 scored · #88 of 151 in Health Care
Trend 64th (it is 8.1% below its highest point of the past year) and valuation 56th (price to earnings 26, price to book 3); weakest is growth (41st, revenue growth year over year 6.4%, 3-year revenue CAGR 5.6%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, LH's dividend was covered by reported results (earnings payout 27%, free-cash-flow payout 20%). This describes past coverage, not a forecast.
- Earnings payout27% dividends / net income
- Free-cash-flow payout20% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Labcorp looks technically
Labcorp (LH) is trading 11.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 54 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It made a new 20-day low about 12 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 11.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +11.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $319.90 | $319.90 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $281.27 | $281.27 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes below 303.13. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 5 |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 54 trading days ago — a "golden cross", a bullish long-term signal | 54 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend) | 18.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30) | 50.3 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($302.71 to $323.84) — its "stochastic" reading is 54 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 54.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $341.80 | $341.80 |
|---|---|---|
| From the 52-week high | it is 8.1% below its 52-week high (its highest price of the past year) | -8.1% |
| Above the 52-week low | it is 28.5% above its 52-week low (its lowest price of the past year) | +28.5% |
| Below the 52-week high | it is 8.1% below its highest point of the past year | 8.1% |
| Since a 20-day breakout | it made a new 20-day low about 12 trading days ago | 12 sessions |
| Since a 55-day breakout | it made a new 55-day high about 33 trading days ago | 33 sessions |
| All-time high | its highest closing price on record is $341.80 (set on 2026-08-27) | $341.80 |
| Given back of the 52-week move | over the past year its closes ranged ($246.64 to $339.34), and it has given back roughly a quarter of its rise from last year’s low — 27% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $279.08 to $282.05. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 27.1% |
| From the all-time high | it is 8.1% below its all-time high | -8.1% |
| Nearest price level | it is trading 3.1% above a support level at $304.29 — a price it turned at twice since 2026-09-10, most recently on 2026-09-24. Since 2024-10-08 it has 11 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -3.1% |
| All-time low | its lowest closing price on record is $40.02 (set on 2005-09-21) | $40.02 |
| Above the all-time low | it is 685.2% above its all-time low | +685.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 35th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $6.76 between its high and its low — about 2.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $6.76 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $300.70 and $325.30 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $300.70 – $313.00 – $325.30 |
| Typical daily range (% of price) | its price moves about 2.2% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.1% |
| Stretch from the 200-day average | it is trading 4.9 daily ranges above its 200-day average price (11.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.89× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Open gap | it gapped 5.5% below the previous close 12 sessions ago and has not traded back through the level it left behind at 320.99 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -5.5% |
| Gap filled | a 3.0% gap down opened on 2026-07-30 has been "filled" 49 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 49 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 5 sessions in a row, a +3.15% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 5 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 4.3 percentage points (the stock lost 3.3% while the market gained 1.0%) | -4.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 9.3 percentage points (the stock gained 13.1% while the market gained 3.8%) | +9.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 3.0 percentage points (the stock gained 14.5% while the market gained 17.5%) | -3.0% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 1.8 percentage points (the stock gained 13.2% while the market gained 15.0%) | -1.8% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: lagging the market over 6 months — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 9.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 10% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $285.33 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +10.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-07-30 (its 8-K), so the typical buyer over that stretch is under water. That average is $318.76 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -1.4% |
Price levels it has turned at before
LH last closed at $314.20 on 2026-10-08. Since 2024-10-08 it has turned at 11 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $304.29 | Support | 3.1% below the last close | turned there twice · 2026-09-10 to 2026-09-24 |
| $291.32 | Support | 7.3% below the last close | turned there five times · 2025-10-01 to 2026-07-07 |
| $280.61 | Support | 10.7% below the last close | turned there five times · 2025-07-24 to 2026-04-21 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes below $303.13.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $326.73 and $364.92 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 11 trading days, since 2026-09-24.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · On a winning streak (5+ higher closes in a row) · Trading inside the Ichimoku cloud · Elliott wave 5 candidates | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.72 mean, 1=Strong Buy…5=Strong Sell) — 16 analysts
- Mean price target$344.81 range $293.00 – $385.00; median $352.50
Analyst estimates, as of 2026-10-03. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for LH
- Consensus EPS estimate$4.65 next reporting period, as of 2026-10-03
- Estimate change, 30 days-$0.0007 (-0.0%) from $4.65, on 2026-08-29, 35-day window
- Readings revised upward14% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on managed care organizations and government reimbursement policies for pricing and patient volume.","Significant regulatory oversight regarding clinical laboratory testing and data privacy.","Risks associated with integrating acquisitions and managing complex global operations."]
What changed in the latest 10-Q
AI-assisted comparison of LH's 10-Q filed 2026-05-04 against the prior one filed 2025-10-31.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-04) references 'Annual Report' without specifying form type, while older filing (2025-10-31) explicitly states 'Annual Report on Form 10-K'
- Removed:
- Removed from item 1: 'of 2014' after 'U.S. Protecting Access to Medicare Act' (older filing: 2025-10-31)
- Removed from item 2: 'fines, penalties, assessments, refunds, repayments, damage to the Company's reputation, unanticipated compliance expenditures, and/or exclusion or debarment from or ineligibility' replaced with 'significant monetary damages, and penalties, and/or exclusion from or ineligibility' (2025-10-31 to 2026-05-04)
- Removed from item 3: specific regulatory references 'including the U.S. Health Insurance Portability and Accountability Act of 1996, the U.S. Health Information Technology for Economic and Clinical Health Act, the European Union's General Data Protection Regulation and similar laws' (2025-10-31)
- Removed from item 4: detailed description 'regarding the operation of clinical laboratories, the development and commercialization of laboratory-developed tests (LDTs), and the delivery of clinical laboratory test results, including, but not limited to, the U.S. Clinical Laboratory Improvement Act of 1967,' and 'the European Union In Vitro Diagnostics Regulation,' (2025-10-31)
- Removed from item 6: 'current' before 'good manufacturing practice' (2025-10-31 had 'current good manufacturing practice')
- Removed from item 7: 'the' before 'Animal Welfare Act' and changed to 'U.S. Animal Welfare Act' (2025-10-31 had 'the Animal Welfare Act')
- Removed from item 9: 'LDTs' abbreviation, now written as 'laboratory-developed tests' (2025-10-31 used 'LDTs')
- Removed from item 9: 'Medicine and Healthcare products Regulatory Agency in the United Kingdom' replaced with 'Medicines and Healthcare Products Regulatory Agency in the U.K.' (2025-10-31)
- Removed from item 10: 'or reimbursement' after 'changes in government regulations' and reworded conjunction structure (2025-10-31)
- Removed from item 14: detailed explanation 'as a result of changes in business models, including risk based or network approaches, out-sourced laboratory network management or utilization management companies, or other changes in strategy or business models by MCOs' replaced with 'as a result of changes in strategy or business models' (2025-10-31)
- Reworded:
- Item 1: 'U.S.' changed from 'United States (U.S.)' (2025-10-31 had full form with abbreviation)
- Item 2: Restructured description to be more concise, removing intermediate phrases about damages and consequences
- Item 3: Simplified to remove explicit regulatory act citations
- Item 4: Simplified licensing law references and removed specific mention of LDTs and EU IVD Regulation details
- Item 6: Capitalization change 'Current Good Manufacturing Practice' to 'Current Good Manufacturing Practice' (inconsistent capitalization between versions)
- Item 7: Changed 'the Animal Welfare Act' to 'the U.S. Animal Welfare Act'
- Item 9: Changed 'LDTs' to 'laboratory-developed tests'
- Item 14: Simplified MCO risk description from detailed business model variations to general statement
- Notes:
- Older filing text appears truncated at end of item 17, preventing full comparison of remaining risk factors
- Newer filing also appears truncated, ending mid-sentence in item 22
- Comparison limited to sections where both texts are available and readable
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 5 sells ($3M) — 4 selling insiders
- Last 180 days · read to 2026-10-040 buys · 9 sells ($5M) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-17. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about LH's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 19 matched disclosures for LH from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding LH as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 12,606,919
- Reported value $3,529,937,527
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about LH's institutional holders → See what each manager we track holds →
Short interest (FINRA)
LH had 2,448,617 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
LH had 3.02% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.31 days to cover at the same settlement.
- Reported short interest (shares) 2,448,617
- Short interest (% of shares outstanding) 3.02%
- Prior settlement (shares) 2,103,302
- Reported change 16.42%
- Days to cover (reported) 3.31
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Quest Diagnostics (DGX)
- ICON plc (ICLR)
- Syneos Health
- Parexel International
- Charles River Laboratories (CRL)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare LH vs…
Labcorp is found in…
Frequently asked questions
What does Labcorp (LH) do?
Labcorp is a global life sciences company that provides vital diagnostics and drug development services. The company operates through two primary segments: Diagnostics Laboratories (Dx), which provides comprehensive clinical laboratory testing, and Biopharma Laboratory Services (BLS), which offers specialized research and development support for pharmaceutical and biotechnology companies.
What sector is Labcorp (LH) in?
Labcorp (LH) is classified in the Health Care sector. Its industry is diagnostic laboratories and research services. It trades on NYSE.
Does LH pay a dividend?
Yes — Labcorp (LH) pays a dividend, with an indicated yield of about 0.90% and at least 4 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-09-03). Informational only — not financial advice.
Who are Labcorp's (LH) competitors?
Notable peers of Labcorp (LH) include Quest Diagnostics, ICON plc, Syneos Health, Parexel International and Charles River Laboratories. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in LH?
Yes — we hold 19 matched STOCK Act disclosures for LH from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Labcorp (LH) overbought or oversold right now?
Labcorp (LH) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 50, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LH come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.